{"name":"Immatics","slug":"immatics","ticker":"IMTX","exchange":"NASDAQ","domain":"immatics.com","description":"Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T","hq":"Tuebingen, Germany / Houston, TX","founded":0,"employees":"589","ceo":"Harpreet Singh","sector":"Cell Therapy / Immuno-Oncology","stockPrice":11.16,"stockChange":0.37,"stockChangePercent":3.43,"marketCap":"$1.8B","metrics":{"revenue":56378925.75479999,"revenueGrowth":-64.9,"grossMargin":-280.9,"rdSpend":0,"netIncome":-229467353.39130238,"cash":548226814.4438976,"dividendYield":0,"peRatio":-5.9,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"IMA201 patent cliff ($0.0B at risk)","drug":"IMA201","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"IMA101 patent cliff ($0.0B at risk)","drug":"IMA101","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"IMA203","genericName":"IMA203","slug":"ima203","indication":"PRAME-positive melanoma","status":"phase_3"},{"name":"APVAC1 vaccine plus Poly-ICLC and GM-CSF","genericName":"APVAC1 vaccine plus Poly-ICLC and GM-CSF","slug":"apvac1-vaccine-plus-poly-iclc-and-gm-csf","indication":"Non-small cell lung cancer","status":"phase_1"},{"name":"APVAC2 vaccine plus Poly-ICLC and GM-CSF","genericName":"APVAC2 vaccine plus Poly-ICLC and GM-CSF","slug":"apvac2-vaccine-plus-poly-iclc-and-gm-csf","indication":"Non-small cell lung cancer","status":"phase_1"},{"name":"IMA901","genericName":"IMA901","slug":"ima901","indication":"Metastatic renal cell carcinoma (in combination with sunitinib)","status":"phase_3"},{"name":"paclitaxel plus carboplatin","genericName":"paclitaxel plus carboplatin","slug":"paclitaxel-plus-carboplatin","indication":"Non-small cell lung cancer","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"IMA203 Product","genericName":"IMA203 Product","slug":"ima203-product","indication":"Other","status":"phase_1"},{"name":"nivolumab plus relatlimab","genericName":"nivolumab plus relatlimab","slug":"nivolumab-plus-relatlimab","indication":"Malignant pleural mesothelioma","status":"phase_3"}]}],"pipeline":[{"name":"IMA203","genericName":"IMA203","slug":"ima203","phase":"phase_3","mechanism":"IMA203 is a T-cell engager that redirects patient T cells to recognize and kill cancer cells expressing the PRAME antigen.","indications":["PRAME-positive melanoma","PRAME-positive solid tumors"],"catalyst":""},{"name":"IMA203 Product","genericName":"IMA203 Product","slug":"ima203-product","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"APVAC1 vaccine plus Poly-ICLC and GM-CSF","genericName":"APVAC1 vaccine plus Poly-ICLC and GM-CSF","slug":"apvac1-vaccine-plus-poly-iclc-and-gm-csf","phase":"phase_1","mechanism":"APVAC1 vaccine targets tumor antigens, Poly-ICLC is a Toll-like receptor 3 agonist, and GM-CSF is a granulocyte-macrophage colony-stimulating factor.","indications":["Non-small cell lung cancer","Melanoma"],"catalyst":""},{"name":"APVAC2 vaccine plus Poly-ICLC and GM-CSF","genericName":"APVAC2 vaccine plus Poly-ICLC and GM-CSF","slug":"apvac2-vaccine-plus-poly-iclc-and-gm-csf","phase":"phase_1","mechanism":"APVAC2 vaccine plus Poly-ICLC and GM-CSF is a cancer immunotherapy that targets tumor cells by stimulating the immune system through activation of dendritic cells and subsequent activation of T cells.","indications":["Non-small cell lung cancer"],"catalyst":""},{"name":"IMA901","genericName":"IMA901","slug":"ima901","phase":"phase_3","mechanism":"IMA901 is a personalized neoantigen vaccine that trains the immune system to recognize and attack cancer cells expressing patient-specific tumor mutations.","indications":["Metastatic renal cell carcinoma (in combination with sunitinib)"],"catalyst":""},{"name":"nivolumab plus relatlimab","genericName":"nivolumab plus relatlimab","slug":"nivolumab-plus-relatlimab","phase":"phase_3","mechanism":"Nivolumab plus relatlimab is a combination immunotherapy that targets the PD-1/PD-L1 axis to enhance anti-tumor immune responses.","indications":["Malignant pleural mesothelioma"],"catalyst":""},{"name":"paclitaxel plus carboplatin","genericName":"paclitaxel plus carboplatin","slug":"paclitaxel-plus-carboplatin","phase":"phase_3","mechanism":"Paclitaxel works by inhibiting cell division, while carboplatin interferes with DNA repair, both leading to cell death in rapidly dividing cancer cells.","indications":["Non-small cell lung cancer","Ovarian cancer","Breast cancer"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Immatics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Immatics reported its financial results for the fourth quarter and full year 2023, highlighting progress in its pipeline and commercial operations.","drugName":"","sentiment":"neutral"},{"date":"2023-12-04","type":"deal","headline":"Immatics Enters into Collaboration with Bristol Myers Squibb","summary":"Immatics entered into a collaboration with Bristol Myers Squibb to develop and commercialize T-cell therapies for cancer.","drugName":"","sentiment":"positive"},{"date":"2023-09-25","type":"trial","headline":"Immatics Announces Positive Interim Results from Phase 1/2 Clinical Trial of IMA201","summary":"Immatics announced positive interim results from a Phase 1/2 clinical trial of its T-cell therapy IMA201 for the treatment of solid tumors.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-02","type":"pipeline","source":"simplywall.st","summary":"Is Immatics (IMTX) Building a PRAME-Focused Platform or Stretching Its Oncology Ambitions Too Thin? - simplywall.st","headline":"Is Immatics (IMTX) Building a PRAME-Focused Platform or Stretching Its Oncology Ambitions Too Thin?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-15","type":"pipeline","source":"simplywall.st","summary":"Assessing Immatics (IMTX) Valuation After Strong One Year Return And High Price To Sales Ratio - simplywall.st","headline":"Assessing Immatics (IMTX) Valuation After Strong One Year Return And High Price To Sales Ratio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQUVZWdW5kU0xiVkh6QmFLdDMwSEZyYWQ2RDJFZTVWdTgwM0ZEbTJLVHd6ZEdmNnJ3YUVwM2VJQ1Qxd0oyMWtYcDVjQjdfMkNuUE84TmRuS2RjTWNucTVic0tpN1pvZDJIVkxHbVZIYm1fMUp2NmdZRlhNbWt5VWtiRUhzVEtOaUd5bHV0c2RmM1pnclFKZmd6NXZMN2Jjdw?oc=5","date":"2025-12-05","type":"pipeline","source":"The Pharma Letter","summary":"Immatics announces $125 million underwritten offering - The Pharma Letter","headline":"Immatics announces $125 million underwritten offering","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-05","type":"earnings","source":"simplywall.st","summary":"Revenues Not Telling The Story For Immatics N.V. (NASDAQ:IMTX) After Shares Rise 28% - simplywall.st","headline":"Revenues Not Telling The Story For Immatics N.V. (NASDAQ:IMTX) After Shares Rise 28%","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE1QVHpYRFR2YVoweWMxaS05SHlrVmRNY1p4bUI2bDVvanh1SDZqMVRzYlRnWENNR0t6cVExUlJXYXFCVkVjMnhuVWRvZkNIWk5iTEhwM1JPZkMxTjNaZDBERkRwak9xMUhW?oc=5","date":"2025-07-09","type":"regulatory","source":"MarketBeat","summary":"Immatics (IMTX) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat","headline":"Immatics (IMTX) FDA Approvals, PDUFA Dates & Drug Alerts 2026","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPQ2RrX2J1MGtKLVRrUVJKWEwwVVhEUTFLejRjNzg1LUtHTWZFX3RyWUl6WGNrSTN4Z3NILWJNLVlzMUVCQ1hNc25MaV8yV2tXZ3dPYnhJSXd4TERJVDg0NEZWTU9YVkNVNTN3U1JVeFlyazREU3VtVTI5QkM4eVQ3Y0pmNDRCZzB0TzdyRkVpTHpJVGxzMGwyWXNzZEVlRW9VbmMtcw?oc=5","date":"2025-04-30","type":"pipeline","source":"The Business Journals","summary":"Immatics US opens 100,000-square-foot Stafford cell-therapy manufacturing plant (PHOTOS) - The Business Journals","headline":"Immatics US opens 100,000-square-foot Stafford cell-therapy manufacturing plant (PHOTOS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1hdC11U05mOVJ2TXZfQXFXb1RFWC1DQXRjZDVzOUtHSEdLTEFaV1RQRmhtYmVkSnlobEhUNzNIMm40bXdKVnpFWGZPanR5OFRpYmRn?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"IMTX Stock Price, News & Analysis - Stock Titan","headline":"IMTX Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE5LdXkxSzV5RnV3YzNiOXd0VlJkTXlZRVV0NFRPQTJpaWYzMzBJVGZnUjRyMjdCZENPQTRrcVFlcTRFX0pVSFpCV3NZbUZEdEpOZlE?oc=5","date":"2024-06-08","type":"pipeline","source":"webull.com","summary":"Experience real-time quotes, in-depth charts, and analyst ratings - webull.com","headline":"Experience real-time quotes, in-depth charts, and analyst ratings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTFBBYm9sWUt4TjJVRjRNakR3Y3E5V2lUQUxxak9za3hkTFJuUE05Z3lOcDdRNUphZkZpeWVSWGRYbFZVRFVCcjVnSkZqYkF0bWFL?oc=5","date":"2024-03-21","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPc1pfUmtrcVFFWFNkOEF4OFFHeERMbk1vdFZmbjRwbF9vVjYxcmNuNDRUaHk1dXFzZlhNQzdneG54MHhmVk1NdEY4SzhXdHd0UXZLaWdCc3VSUFFoSVVYeWw0UEZsWjhHT3BjSFU3aEN5NFdLN042WDNlbV9TZlVSSWpHWnB1dml1ajdZX2VwcG03a1dKT0ctUQ?oc=5","date":"2023-09-11","type":"deal","source":"The Business Journals","summary":"Moderna enters cancer collaboration with Immatics worth $1.8B - The Business Journals","headline":"Moderna enters cancer collaboration with Immatics worth $1.8B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE55YmZLU21BVVEtVkRUck82WmhIVGFzak1CelJKN2FQV0F5QjE5WHVGRXBrSDFNUUVNa1U1dDRrdlBWaU93dGFNTjN3YllXUWxTR01yMmE0eGRUeGFV?oc=5","date":"2020-07-03","type":"pipeline","source":"TradingView","summary":"IMTX Stock Price and Chart — NASDAQ:IMTX - TradingView","headline":"IMTX Stock Price and Chart — NASDAQ:IMTX","sentiment":"neutral"}],"patents":[{"drugName":"IMA201","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0},{"drugName":"IMA101","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":7,"phaseCounts":{"phase_3":4,"phase_1":3},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","Novartis"],"therapeuticFocus":["Cancer Immunotherapy","T-Cell Therapies"],"financials":{"source":"yahoo_finance","revenue":56378925.75479999,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":56378925.75479999},{"period":"2024-12-31","value":182028962.313},{"period":"2023-12-31","value":63073236.93659999},{"period":"2022-12-31","value":201881782.56179997}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":214731916.44959998,"rdSpendHistory":[{"period":"2025-12-31","value":214731916.44959998},{"period":"2024-12-31","value":172969273.3362},{"period":"2023-12-31","value":138608802.61139998},{"period":"2022-12-31","value":124727247.19619998}],"sgaSpend":59787405.955199994,"operatingIncome":-212610669.0048,"operatingIncomeHistory":[{"period":"2025-12-31","value":-212610669.0048},{"period":"2024-12-31","value":-45105710.39699999},{"period":"2023-12-31","value":-118823731.45499998},{"period":"2022-12-31","value":34988901.9612}],"netIncome":-229467344.04659998,"netIncomeHistory":[{"period":"2025-12-31","value":-229467344.04659998},{"period":"2024-12-31","value":17775960.1404},{"period":"2023-12-31","value":-110558342.18219998},{"period":"2022-12-31","value":32359536.3234}],"eps":0.14,"epsHistory":[{"period":"2024-12-31","value":0.14},{"period":"2023-12-31","value":-1.18},{"period":"2022-12-31","value":0.55},{"period":"2021-12-31","value":-1.48}],"cash":404062595.6004,"cashHistory":[{"period":"2025-12-31","value":404062595.6004},{"period":"2024-12-31","value":276542450.4744},{"period":"2023-12-31","value":255194477.84159997},{"period":"2022-12-31","value":173483231.9682}],"totalAssets":656858989.1886,"totalLiabilities":91388853.2964,"totalDebt":18263052.753,"equity":565470135.8922,"operatingCashflow":-206314675.76279998,"operatingCashflowHistory":[{"period":"2025-12-31","value":-206314675.76279998},{"period":"2024-12-31","value":-184592915.03399998},{"period":"2023-12-31","value":21291904.418399997},{"period":"2022-12-31","value":116961799.50179999}],"capex":-7948837.478999999,"capexHistory":[{"period":"2025-12-31","value":-7948837.478999999},{"period":"2024-12-31","value":-19250086.944},{"period":"2023-12-31","value":-36160494.0246},{"period":"2022-12-31","value":-7259665.676999999}],"freeCashflow":-214263513.24179998,"dividendsPaid":null,"buybacks":null,"employees":589,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":15960751.699199999,"ebit":-41282559.0276,"ebitda":-37580888.7894,"period":"2025-12-31","revenue":23082583.0158,"epsBasic":null,"netIncome":-41698398.28439999,"rdExpense":57986214.5676,"epsDiluted":null,"grossProfit":null,"operatingIncome":-45416421.75179999},{"sga":14803176.689399999,"ebit":-58919516.719799995,"ebitda":-55339327.612799995,"period":"2025-09-30","revenue":6058871.4185999995,"epsBasic":-0.42,"netIncome":-59040997.850999996,"rdExpense":55105710.05279999,"epsDiluted":-0.42,"grossProfit":null,"operatingIncome":-63816140.777399994},{"sga":14928162.083999999,"ebit":-83056883.019,"ebitda":-79522249.3362,"period":"2025-06-30","revenue":5533231.9086,"epsBasic":-0.58,"netIncome":-82172640.5544,"rdExpense":52687768.30679999,"epsDiluted":-0.58,"grossProfit":null,"operatingIncome":-62057000.55059999},{"sga":14095315.482599998,"ebit":-47424364.67999999,"ebitda":-43756568.988,"period":"2025-03-31","revenue":21705407.499599997,"epsBasic":-0.33,"netIncome":-46554139.268999994,"rdExpense":48952223.5224,"epsDiluted":-0.33,"grossProfit":null,"operatingIncome":-41319937.83719999},{"sga":15797219.4072,"ebit":50815323.56339999,"ebitda":54408361.636199996,"period":"2024-12-31","revenue":65707274.92559999,"epsBasic":null,"netIncome":52403922.97139999,"rdExpense":48883306.342199996,"epsDiluted":null,"grossProfit":null,"operatingIncome":1054783.2833999998},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-0.05,"netIncome":null,"rdExpense":null,"epsDiluted":-0.08,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":11.16,"previousClose":10.79,"fiftyTwoWeekHigh":12.41,"fiftyTwoWeekLow":4.48,"fiftyTwoWeekRange":"4.478 - 12.41","fiftyDayAverage":10.48,"twoHundredDayAverage":9.26,"beta":1.31,"enterpriseValue":1254126792.482995,"forwardPE":-5.9,"priceToBook":2.62,"priceToSales":31.6,"enterpriseToRevenue":22.25,"enterpriseToEbitda":-6.21,"pegRatio":0,"ebitda":-201933187.76970237,"ebitdaMargin":0,"freeCashflow":-149737464.76777437,"operatingCashflow":-206314675.76279998,"totalDebt":18263052.753,"debtToEquity":3.2,"currentRatio":11.72,"returnOnAssets":-18.1,"returnOnEquity":-37.1,"analystRating":"1.0 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":8,"targetMeanPrice":18.75,"targetHighPrice":25,"targetLowPrice":11,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":17.9,"institutionHeldPercent":75.8,"sharesOutstanding":136673161,"floatShares":67268206,"sharesShort":5157669,"shortRatio":16.8,"shortPercentOfFloat":3.9,"epsTrailing":-2.01,"epsForward":-1.89,"revenuePerShare":0.39,"bookValue":4.26,"officers":[{"age":50,"name":"Dr. Harpreet  Singh Ph.D.","title":"CEO, MD, Member of Management Board & Executive Director"},{"age":55,"name":"Dr. Venkat  Ramanan Ph.D.","title":"Chief Financial Officer"},{"age":52,"name":"Ms. Amie  Krause","title":"Chief People Officer"},{"age":null,"name":"Dr. Hans-Georg  Rammensee Ph.D.","title":"Co-Founder & Member of the Scientific Advisory Board"},{"age":55,"name":"Dr. Toni  Weinschenk Ph.D.","title":"Co-Founder & Chief Innovation Officer"},{"age":48,"name":"Mr. Steffen  Walter Ph.D.","title":"Chief Operations Officer"},{"age":null,"name":"Mr. Ephraim  Hofsäß M.Sc.","title":"Vice President of SEC Reporting & Accounting"},{"age":null,"name":"Mr. Edward A. Sturchio","title":"General Counsel & Secretary"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.immatics.com","phone":"49 7071 5397 0"}}